Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

Study Overview
=================
Brief Summary
-----------------
Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (TBI). Endocrine complications are frequent transplant-related side effects. Investigators have been well described in children studies but less in adulthood. The objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-HSCT.

Detailed Description
-----------------
Patients & Methods Inclusion criteria are : patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease; adult and in complete remission at exploration. Exclusion criteria are : anteriority of brain radiotherapy and prior HSCT. Twelve months after HSCT, each patient underwent fasting measurement of IGF1, TSH, fT4, FSH, LH, sex steroids, glycemia, insulin level, and lipid profile. Unless contraindication, adrenal and growth hormone functions were assessed with insulin hypoglycemia test. A dual X-ray absorptiometry was also performed. Investigators will assess the prevalence of endocrine, bone and metabolic disorders 12 months after allo-HSCT and describe some of their risk factors.

Official Title
-----------------
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

Conditions
-----------------
Endocrine System Diseases, Osteoporosis, Metabolic Syndrome, Adrenal Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease adult and in complete remission at exploration. Exclusion Criteria: anteriority of brain radiotherapy prior HSCT pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adrenal insuffisiency prevalence | insulin hypoglycemia test | 12 month post-alloHSCT | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypothyroidism prevalence | fT4, TSH | 12 month post-alloHSCT | 
| Growth hormon Deficiency prevalence | insulin hypoglycemia test | 12 month post-alloHSCT | 
| Premature ovarian failure prevalence | FSH, LH, estradiol | 12 month post-alloHSCT | 
| Prevalence of elevated FSH in men | FSH, testosterone | 12 month post-alloHSCT | 
| Prevalence of low bone mineral density | dual X-ray absorptiometry | 12 month post-alloHSCT | 
| Prevalence of obesity | BMI | 12 month post-alloHSCT | 
| Prevalence of dyslipidemia |  | 12 month post-alloHSCT | 
| Prevalence of hyperglycemia and insulin-resistance | glycemia and HOMA2-IR index | 12 month post-alloHSCT |